Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770247 | 1.00 | LTA4H (0.67) | LTA4HALDH1A1SMN1; SMN2FKBP1AHRH3 | |
| SCHEMBL2770248 | 1.00 | LTA4H (0.67) | LTA4HALDH1A1SMN1; SMN2FKBP1AHRH3 | |
| SCHEMBL2772367 | 0.92 | LTA4H (0.57) | LTA4HALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL2772130 | 0.92 | LTA4H (0.57) | LTA4HALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL2772128 | 0.92 | LTA4H (0.57) | LTA4HALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL10507857 | 0.90 | LTA4H (0.62) | LTA4HALDH1A1SMN1; SMN2FKBP1A | |
| SCHEMBL952722 | 0.86 | LTA4H (0.63) | LTA4HALDH1A1SMN1; SMN2FKBP1AACE | |
| SCHEMBL952721 | 0.86 | LTA4H (0.63) | LTA4HALDH1A1SMN1; SMN2FKBP1AACE | |
| SCHEMBL19465330 | 0.86 | LTA4H (0.63) | LTA4HALDH1A1SMN1; SMN2FKBP1AACE | |
| SCHEMBL1116547 | 0.84 | ALDH1A1 (0.56) | LTA4HALDH1A1SMN1; SMN2HRH3ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1057894-B1 | Esterase genes and uses of the same | SUMITOMO CHEMICAL CO (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-6828129-B2 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-12-07 | — | — | US | disclosed |
| US-6812008-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE FOR USE IN THE GENERATION OF S-N-BENZYLAZETIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-02 | — | — | US | disclosed |
| US-6537790-B1 | Isolated protein of given sequence which can produce N-substituted cyclic imino acids by hydrolization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020173013-A1 | Esterace genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-21 | — | — | US | disclosed |
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-07 | — | — | US | disclosed |
| EP-1057894-A2 | Esterase genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | IMPDH2, INHA, IMPDH1 | LTA4H 3520/4885ALDH1A1 2545/4885SMN1; SMN2 3197/4885 |
| US-20020173013-A1 | Esterace genes and uses of the same | ACOT7, COASY, IMPA1 | LTA4H 2045/4885ALDH1A1 707/4885SMN1; SMN2 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.